Statement by Chip Davis, President and CEO, GPhA, Regarding the Nomination of Dr. Robert Califf as Next FDA Commissioner
Contact: Steve Arnoff 202.249.7113
WASHINGTON, DC (Sept. 16, 2015) –
“The Generic Pharmaceutical Association (GPhA) congratulates Dr. Robert Califf on his nomination for Commissioner of the Food and Drug Administration (FDA). Dr. Califf’s deep expertise in research and health care quality will certainly aid the FDA in carrying out its mission.
This nomination comes at a critical time for FDA. Following the approval of the first biosimilar in the United States, GPhA and its Biosimilars Council are eager to gain clarity on several outstanding guidance documents and continue the discussion on biosimilar naming. GPhA also looks forward to the agency’s meaningful progress under Dr. Califf’s leadership toward our shared commitment to GDUFA goals of safety, access and transparency.
GPhA looks forward to continuing to work together with FDA on process enhancements which can help expedite patient access to safe and effective generic drugs and biosimilars.”
GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 86 percent of the prescriptions dispensed in the U.S. but consume just 27 percent of the total drug spending. Additional information is available at gphaonline.org. Follow us on twitter: @gpha.